Arbutus Biopharma Corp APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Arbutus Biopharma Corp (ABUS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- Arbutus Biopharma Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.63M, a 88.08% increase year-over-year.
- Arbutus Biopharma Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.36M, a 61.87% decline year-over-year.
- Arbutus Biopharma Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.26M, a 41.53% decline year-over-year.
- Arbutus Biopharma Corp apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $864.00K, a 72.83% decline year-over-year.
- Arbutus Biopharma Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.95M, a 22.62% decline from fiscal 2024.
- Arbutus Biopharma Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $8.99M, a 3.39% decline from fiscal 2023.
- Arbutus Biopharma Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $9.30M, a 29.50% increase from fiscal 2022.
- Arbutus Biopharma Corp apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $7.18M, a 12.48% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.63M 10-Q · filed 2026-08-12 | $2.98M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $1.36M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $6.95M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $1.26M 10-Q · filed 2025-11-13 | $2.13M derived: sum of 2 quarters · filed 2026-08-12 | $5.69M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $864.00K 10-Q · filed 2026-08-12 | $4.43M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $3.56M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $8.99M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $2.16M 10-Q · filed 2025-11-13 | $5.34M derived: sum of 2 quarters · filed 2025-11-13 | $7.35M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $3.18M 10-Q · filed 2025-11-13 | $5.19M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $2.01M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $9.30M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $2.48M 10-Q · filed 2024-11-06 | $5.45M derived: sum of 2 quarters · filed 2024-11-06 | $7.58M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $2.96M 10-Q · filed 2024-11-06 | $5.09M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $2.13M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $7.18M 10-K · filed 2024-03-05 | |||
| 2022-09-30 | $1.72M 10-Q · filed 2023-11-07 | $3.78M derived: sum of 2 quarters · filed 2023-11-07 | $5.51M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $2.06M 10-Q · filed 2023-11-07 | $3.80M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $1.74M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $6.38M 10-K · filed 2023-03-02 | |||
| 2021-09-30 | $1.55M 10-Q · filed 2022-11-09 | $3.31M derived: sum of 2 quarters · filed 2022-11-09 | $4.95M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $1.76M 10-Q · filed 2022-11-09 | $3.40M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $1.65M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $6.14M 10-K · filed 2022-03-03 | |||
| 2020-09-30 | $1.66M 10-Q · filed 2021-11-04 | $3.25M derived: sum of 2 quarters · filed 2021-11-04 | $4.71M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $1.60M 10-Q · filed 2021-11-04 | $3.06M derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $1.46M 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $7.20M 10-K · filed 2021-03-04 | |||
| 2019-09-30 | $1.59M 10-Q · filed 2020-11-05 | $5.51M derived: sum of 2 quarters · filed 2020-11-05 | $7.17M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $3.92M 10-Q · filed 2020-11-05 | $5.58M derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $1.67M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $6.69M 10-K · filed 2020-03-05 | |||
| 2018-09-30 | $1.66M 10-Q · filed 2019-11-06 | $3.52M derived: sum of 2 quarters · filed 2019-11-06 | $5.03M derived: sum of 3 quarters · filed 2019-11-06 | $6.72M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $1.86M 10-Q · filed 2019-11-06 | $3.37M 10-Q · filed 2018-08-03 | $5.06M derived: sum of 3 quarters · filed 2019-11-06 | $8.74M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-03-31 | $1.51M 10-Q · filed 2019-11-06 | $3.20M derived: sum of 2 quarters · filed 2019-11-06 | $6.88M derived: sum of 3 quarters · filed 2019-11-06 | $11.94M derived: sum of 4 quarters · filed 2019-11-06 |
| 2017-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $5.37M derived: sum of 2 quarters · filed 2019-03-07 | $10.43M derived: sum of 3 quarters · filed 2019-03-07 | $14.86M 10-K · filed 2019-03-07 |
| 2017-09-30 | $3.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $8.74M derived: sum of 2 quarters · filed 2017-11-02 | $13.17M 10-Q · filed 2017-11-02 | $17.79M derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-06-30 | $5.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $9.49M 10-Q · filed 2017-08-03 | $14.12M derived: sum of 3 quarters · filed 2018-03-16 | $18.38M derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-03-31 | $4.43M 10-Q · filed 2017-05-04 | $9.05M derived: sum of 2 quarters · filed 2018-03-16 | $13.31M derived: sum of 3 quarters · filed 2018-03-16 | $34.68M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $8.88M derived: sum of 2 quarters · filed 2018-03-16 | $30.25M derived: sum of 3 quarters · filed 2018-03-16 | $38.16M 10-K · filed 2018-03-16 |
| 2016-09-30 | $4.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $25.63M derived: sum of 2 quarters · filed 2016-11-03 | $33.54M 10-Q · filed 2016-11-03 | $40.90M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-06-30 | $21.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $29.28M 10-Q · filed 2016-08-04 | $36.64M derived: sum of 3 quarters · filed 2018-03-16 | $44.14M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-03-31 | $7.91M 10-Q · filed 2016-05-04 | $15.27M derived: sum of 2 quarters · filed 2018-03-16 | $22.77M derived: sum of 3 quarters · filed 2018-03-16 | $27.07M derived: sum of 4 quarters · filed 2018-03-16 |
| 2015-12-31 | $7.36M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $14.86M derived: sum of 2 quarters · filed 2018-03-16 | $19.16M derived: sum of 3 quarters · filed 2018-03-16 | $22.09M 10-K · filed 2018-03-16 |
| 2015-09-30 | $7.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $11.80M derived: sum of 2 quarters · filed 2015-11-05 | $14.73M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $4.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $7.23M 10-Q · filed 2015-08-07 | ||
| 2015-03-31 | $2.93M 10-Q · filed 2015-05-06 | |||
| 2014-12-31 | $3.28M 10-K · filed 2017-03-22 | |||
| 2013-12-31 | $903.00K 10-K · filed 2016-03-09 | |||
| 2012-12-31 | $982.00K 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |